Madrigal Pharmaceuticals Inc (FRA:YDO1)
€ 193.4 -1.45 (-0.74%) Market Cap: 4.17 Bil Enterprise Value: 3.29 Bil PE Ratio: 0 PB Ratio: 5.14 GF Score: 40/100

Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 06:10PM GMT
Release Date Price: €110.45 (-0.54%)
Navin Cyriac Jacob;Rebecca A. Taub
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic;Madrigal Pharmaceuticals, Inc. -

Hello. Welcome to the UBS Global Healthcare Conference. My name is Navin Jacob, senior analyst covering large-cap pharma and SMID cap biotech. Our next presentation and fireside chat is with Madrigal Pharmaceuticals. I'm happy to have with me today, Madrigal's management team; Becky Taub, Chief Medical Officer and Founder; as well as the other founder, Paul Friedman, Chairman and CEO; as well as Marc Schneebaum, CFO. Thank you all 3, for joining us today.

We're going to have a short presentation given by Dr. Taub. And following that, we will do some Q&A. Thank you all for joining us, Paul, Becky and Marc. Becky, do you want to go ahead with your short presentation? And for folks on the line, when you see the slides online, you can scroll through them via the slide deck that's posted online. You can just click on the arrow button to go through.

Go ahead, Becky.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot